| Income Statement | 2025-09-30 | 2025-03-31 | 2024-09-30 | |
|---|---|---|---|---|
| Total operating expenses | - | 42,256 | 28,338 | |
| Total revenues | 1,666 | 52 | 43 | |
| Cost of sales | 1,577 | - | - | |
| Research and development | 27,884 | 27,467 | 19,622 | |
| General and administrative | 23,334 | 14,789 | 8,716 | |
| Total operating costs and expenses | 52,795 | - | - | |
| Loss from operations | -51,129 | -42,204 | -28,295 | |
| Interest income, net | 7,421 | 7,747 | 7,892 | |
| Other (expense) income, net | -100 | 5 | -2 | |
| Total other income, net | 7,321 | 7,752 | 7,890 | |
| Net loss and comprehensive loss | -43,808 | -34,452 | -20,405 | |
| Net loss attributable to common stockholders | - | - | -20,405 | |
| Earnings per share, basic, total | -0.57 | -0.45 | -0.3 | |
| Earnings per share, diluted, total | -0.57 | -0.45 | -0.3 | |
| Weighted average number of shares outstanding, basic, total | 76,729,726 | 76,187,621 | 67,143,744 | |
| Weighted average number of shares outstanding, diluted, total | 76,729,726 | 76,187,621 | 67,143,744 | |
CG Oncology, Inc. (CGON)
CG Oncology, Inc. (CGON)